Hospital
Paul Oliver Memorial Hospital
Paul Oliver Memorial Hospital was paid $3.03M by Medicaid between Jan 2018 and Dec 2024, across 86 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoPAUL OLIVER MEMORIAL HOSPITAL
FRANKFORT, MI 49635
FRANKFORT, MI 49635
33aNPI1427054360assigned 06/24/2005
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$3.03M
24GClaims103,360
24DCodes billed86
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Medicare Defined Swing Bed Hospital Unit providers in Michigan
Rank by total paid#7 of 8
Median peer was paid$5.78M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,937 | $270K | |
| 2019 | 12,405 | $226K | |
| 2020 | 11,369 | $288K | |
| 2021 | 15,633 | $533K | |
| 2022 | 17,483 | $593K | |
| 2023 | 18,642 | $624K | |
| 2024incomplete | 13,891 | $493K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 4,660 | 4,426 | $681K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 2,093 | 2,019 | $432K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 1,190 | 1,148 | $364K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 9.0% | 9,954 | 3,159 | $272K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.1% | 2,668 | 2,576 | $214K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.2% | 1,470 | 1,312 | $188K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 4.3% | 5,043 | 2,006 | $131K |
| 71046 | Radiologic examination, chest; 2 views | 2.4% | 1,578 | 1,532 | $73K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.0% | 1,707 | 791 | $59K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 1,103 | 984 | $47K |
| 80053 | Comprehensive metabolic panel | 1.5% | 9,191 | 8,630 | $45K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 190 | 187 | $43K |
74 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.4% | 4,039 | $42K |
| 80061 | Lipid panel | 1.3% | 4,288 | $39K |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 17,000 | $39K |
| 97161 | 1.2% | 621 | $37K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.0% | 2,065 | $31K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 497 | $29K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 628 | $26K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 739 | $25K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 241 | $25K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,902 | $25K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,162 | $22K |
| 71045 | Radiologic examination, chest; single view | <1% | 344 | $21K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 240 | $18K |
| 97162 | <1% | 230 | $14K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,035 | $13K |
| 85027 | <1% | 2,486 | $10K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,977 | $8K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 461 | $6K |
| 82728 | <1% | 563 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 810 | $4K |
| 83735 | <1% | 1,474 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 18 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 612 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 25 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 15 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 572 | $2K |
| 81001 | <1% | 2,951 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 113 | $2K |
| 82570 | <1% | 445 | $2K | |
| 73630 | <1% | 95 | $2K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 14 | $2K |
| 83540 | <1% | 368 | $2K | |
| 85610 | <1% | 824 | $2K | |
| 84439 | <1% | 272 | $2K | |
| 83550 | <1% | 207 | $1K | |
| 86140 | <1% | 472 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 54 | $984.17 |
| 83690 | <1% | 785 | $862.46 | |
| 87081 | <1% | 316 | $859.25 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 45 | $853.42 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 66 | $819.17 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $684.48 |
| 85652 | <1% | 535 | $671.49 | |
| 73564 | <1% | 15 | $670.86 | |
| 72110 | <1% | 12 | $646.45 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 87 | $516.38 |
| 82043 | <1% | 133 | $491.25 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14 | $467.30 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 25 | $448.14 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 25 | $355.10 |
| 80305 | <1% | 33 | $294.50 | |
| 73610 | <1% | 38 | $256.56 | |
| 87186 | <1% | 66 | $197.08 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $183.54 |
| 81025 | <1% | 326 | $180.85 | |
| 82248 | <1% | 54 | $156.72 | |
| 83880 | <1% | 14 | $147.60 | |
| 87077 | <1% | 51 | $138.59 | |
| 82607 | <1% | 12 | $120.40 | |
| 73130 | <1% | 15 | $94.86 | |
| 82150 | <1% | 54 | $79.06 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 152 | $58.24 |
| 84484 | <1% | 310 | $28.43 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 49 | $21.53 |
| 83605 | <1% | 389 | $18.45 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 444 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 237 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 433 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 812 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 14 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 13 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 14 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 27 | $0.00 |
| 87040 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARINOFF, PETER (PRESIDENT/CEO SOUTH REIGON)
| Provider | Location | Paid |
|---|---|---|
| Munson Healthcare Cadillac | Cadillac, MI | $21.55M |
| Munson Healthcare Cadillac | Cadillac, MI | $50K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.